Psychiatry

News

BMS completes $14bn takeover of Karuna

Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a sha

News

Steve Davis, president and chief executive of Acadia Pharma

Acadia pulls trials of pimavanserin after schizophrenia fail

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.

News

Boehringer licenses Sosei schizophrenia drugs in €755m deal

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activit

News

Minerva slumps as FDA finds fault with schizophrenia filing

Shares in Minerva Neurosciences have lost more than half their value after the FDA rejected its marketing application for roluperidone as a treatment for the negative symp

News

Exercise ‘may be better than drugs for depression’

Doctors should think twice before prescribing drug therapies when faced with someone battling depression, as exercise may be more effective, according to a new study.

News

MindMed says LSD-based therapy effective in anxiety

Psychedelic medicines specialist MindMed has said that its LSD-based treatment MM-120 has shown efficacy in a proof-of-concept study involving patients with generalised an

BMS completes $14bn takeover of Karuna

Acadia pulls trials of pimavanserin after schizophrenia fail

Boehringer licenses Sosei schizophrenia drugs in €755m deal

Minerva slumps as FDA finds fault with schizophrenia filing

Exercise ‘may be better than drugs for depression’

MindMed says LSD-based therapy effective in anxiety

Immunovant's thyroid eye disease drug flunks pivotal trials

Using AI-driven synthetic personas to take your insights fur...

Psychiatry

Editor's Picks